118 related articles for article (PubMed ID: 36218364)
1. Do differences in cell lines and methods used for calculation of IC
Volpe DA; Joshi A; Arya V
Xenobiotica; 2022 Jul; 52(7):751-757. PubMed ID: 36218364
[No Abstract] [Full Text] [Related]
2. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
[TBL] [Abstract][Full Text] [Related]
3. Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays.
Yabut J; Houle R; Wang S; Liaw A; Katwaru R; Collier H; Hittle L; Chu X
Drug Metab Dispos; 2022 Jul; 50(7):909-922. PubMed ID: 35489778
[TBL] [Abstract][Full Text] [Related]
4. Derivation of a System-Independent
Chaudhry A; Chung G; Lynn A; Yalvigi A; Brown C; Ellens H; O'Connor M; Lee C; Bentz J
Drug Metab Dispos; 2018 Mar; 46(3):279-290. PubMed ID: 29317410
[TBL] [Abstract][Full Text] [Related]
5. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
6. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
7. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
[TBL] [Abstract][Full Text] [Related]
8. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
9. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
10. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
11. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
[TBL] [Abstract][Full Text] [Related]
12. Translatability of in vitro Inhibition Potency to in vivo P-Glycoprotein Mediated Drug Interaction Risk.
Lazzaro S; West MA; Eatemadpour S; Feng B; Varma MVS; Rodrigues AD; Temesszentandrási-Ambrus C; Kovács-Hajdu P; Nerada Z; Gáborik Z; Costales C
J Pharm Sci; 2023 Jun; 112(6):1715-1723. PubMed ID: 36682487
[TBL] [Abstract][Full Text] [Related]
13. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
14. Case Study 8: Status of the Structural Mass Action Kinetic Model of P-gp-Mediated Transport Through Confluent Cell Monolayers.
Bentz J; Ellens H
Methods Mol Biol; 2021; 2342():737-763. PubMed ID: 34272715
[TBL] [Abstract][Full Text] [Related]
15. Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.
Li YH; Bi HC; Huang L; Jin J; Zhong GP; Zhou XN; Huang M
Acta Pharmacol Sin; 2014 Feb; 35(2):283-91. PubMed ID: 24362330
[TBL] [Abstract][Full Text] [Related]
16. Combined in silico and in vitro approaches to identify P-glycoprotein-inhibiting pesticides.
Guéniche N; Lakehal Z; Habauzit D; Bruyère A; Fardel O; Le Hégarat L; Huguet A
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23588. PubMed ID: 37985955
[TBL] [Abstract][Full Text] [Related]
17. Loxapine P-glycoprotein interactions in vitro.
Reed A; Huie K; Perloff ES; Cassella JV; Takahashi LH
Drug Metab Lett; 2012 Mar; 6(1):26-32. PubMed ID: 22300294
[TBL] [Abstract][Full Text] [Related]
18. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the IPEC-J2 MDR1 (iP-gp) cell line as a tool for identification of P-gp substrates.
Ozgür B; Saaby L; Langthaler K; Brodin B
Eur J Pharm Sci; 2018 Jan; 112():112-121. PubMed ID: 29146563
[TBL] [Abstract][Full Text] [Related]
20. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
